Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

NCT06123754 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
DRUG: placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Sponsor

3D Medicines (Sichuan) Co., Ltd.